Twitter LinkedIn
    Friday, January 27
    Login
    0 Shopping Cart
    Twitter LinkedIn
    Private Equity InsiderPrivate Equity Insider
    • About Us
    • Digital Events
    • Our Network
      • Reach
      • Sponsors
      • Members
    Private Equity InsiderPrivate Equity Insider
    Home»Investments»SoftBank Plans Billions to Invest in Biotech
    Investments

    SoftBank Plans Billions to Invest in Biotech

    February 25, 20212 Mins Read
    LinkedIn Facebook Twitter Email WhatsApp
    Share
    LinkedIn Facebook Twitter Email WhatsApp

    SoftBank Group Corp. plans to expand its investments in the biotech and health-care sector, opening up a new front in its growing asset management strategy, according to people familiar with the matter. SoftBank has already made a clutch of equity investments in the sector, including a $312 million stake in Pacific Biosciences of California Inc., a U.S. DNA-sequencing company whose stock has risen almost 9-fold in the last year. The Japanese firm is now planning to spend billions investing in public biotech companies, the people said, who asked not to speak publicly because the strategy is private.

    Analysts and investors have been speculating about how founder Masayoshi Son will spend more than $80 billion in assets, after the SoftBank CEO last year unveiled plans to sell off 4.5 trillion yen ($43 billion) in assets and buy back 2.5 trillion yen of its own stock. Shares in the Japanese billionaire’s SoftBank have since surged, reaching the highest close since the company went public in 1994, and flying past a long-standing record two decades ago, as a boom in tech companies helps lift SoftBank’s portfolio.

    SoftBank has already made a number of investments in health-care startups, primarily through its Vision Fund, such as 10x Genomics and Roivant Sciences. The Japanese investor also has a $298 million equity stake in Canadian antibody-drug discovery platform AbCellera Biologics Inc., a small investment in 4D Molecular Therapeutics, and is planning a further $900 million convertible debt investment in PacBio, according to a report by The Wall Street Journal.

     

    Read More

    Source: BNN Bloomberg

    By Ruth David and Giles Turner

    Related

    Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.

    biotech Capital funds Investments
    Share. LinkedIn Facebook Twitter Email WhatsApp

    Related Posts

    CAI raises over $1B for inaugural fund and co-investment programme

    November 18, 2022

    Carlyle targeting $1.6B for second renewables fund

    November 18, 2022

    Vista’s latest flagship fund halfway to $20B target

    November 18, 2022

    MVM closes oversubscribed Fund VI at $500m hard cap

    November 17, 2022

    Comments are closed.

    Other Articles

    Ex-L Catterton Asia Chief’s $500 Million Fund Wins Saudi Backing

    February 7, 2022

    Global software sector sees deals worth $130B in Q2

    August 3, 2022

    Goldman Sachs raises MONETA stake to 10.45% amid offer from PPF

    January 30, 2021

    Meggitt presses ahead and publishes documents for Parker-Hannifin £6.3bn takeover bid

    August 16, 2021

    Private Equity Insider LLC
    1212 Avenue of the Americas
    New York City 10036
    USA

    [email protected]

    Twitter LinkedIn
    © 2023 Private Equity Insider LLC. All rights reserved.
    • About
    • Terms of Use
    • Cookie Policy
    • Privacy Policy
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.

    View Cart Checkout Continue Shopping

    Sign In or Register

    Welcome Back!

    Login to your account below.


    Lost password?